Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference
Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx") a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York on Wednesday, December 4, 2024, at 9:30 AM PT / 12:30 PM ET.
加利福尼亚州雷德伍德市，2024年11月20日(GLOBE NEWSWIRE) -- pulmonx公司(纳斯达克: LUNG) ("Pulmonx")是一家全球领先的微创治疗严重肺部疾病的公司，今天宣布该公司将在2024年12月4日星期三上午9:30点在纽约举行的派杰投资第36届年度医疗健康大会上举行火炉边交流。
A live and archived webcast of the presentation will be available on "Investors" section of the Pulmonx website at .
这次演示的现场直播和存档网络视频将在Pulmonx网站的"投资者"部分提供。
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx's Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a "breakthrough device." The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit .
pulmonx Corporation是一家全球医疗公司，是慢性阻塞性肺疾病（COPD）微创治疗领域的领军企业。Pulmonx的Zephyr内镜瓣膜、Chartis肺功能评估系统和StratX肺部分析平台专为最严重的肺气肿/COPD患者而设计，这些患者尽管接受过医疗管理仍存在明显的症状。Pulmonx获得FDA的预市场批准，用于商业化Zephyr内镜瓣，因被认定为“突破性设备”而入选。Zephyr内镜瓣在全球25多个国家商业上市，被纳入全球治疗指南，并被广泛认为是改善重症肺气肿患者的呼吸、活动和生活质量的标准护理治疗方案。有关Zephyr内镜瓣和该公司的更多信息，请访问。
pulmonx公司(纳斯达克: LUNG)是全球肺部慢性阻塞性疾病(COPD)微创治疗的全球领导者。 pulmonx的Zephyr内支架瓣、Chartis肺功能评估系统、LungTraX平台和StratX肺部分析报告旨在评估和治疗尽管接受医疗管理但仍然症状严重的严重肺气肿/COPD患者。 pulmonx获得FDA预市场批准，开始商业化Zephyr瓣，因为它被评定为"突破性设备"。 Zephyr瓣已在超过25个国家商业化，被纳入全球治疗指南，并被普遍认为是改善严重肺气肿患者呼吸、活动和生活质量的标准疗法选择。有关Zephyr瓣和该公司的更多信息，请访问。
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
联系方式
Brian Johnston
吉尔马丁集团
investors@pulmonx.com
